Ginkgo Bioworks Holdings, Inc.
DNA
$7.71
-$0.14-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -41.69% | -14.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.69% | -14.01% | |||
| Cost of Revenue | -57.57% | -42.97% | |||
| Gross Profit | -37.24% | 0.23% | |||
| SG&A Expenses | -17.79% | 2.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.17% | -18.62% | |||
| Operating Income | -1.90% | 20.65% | |||
| Income Before Tax | 6.46% | -0.79% | |||
| Income Tax Expenses | 87.56% | -64,400.00% | |||
| Earnings from Continuing Operations | 5.81% | 0.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.27% | 0.00% | |||
| EBIT | -1.90% | 20.65% | |||
| EBITDA | -2.77% | 30.67% | |||
| EPS Basic | 1.99% | 2.54% | |||
| Normalized Basic EPS | -5.35% | 26.91% | |||
| EPS Diluted | 2.31% | 2.22% | |||
| Normalized Diluted EPS | -5.35% | 26.91% | |||
| Average Basic Shares Outstanding | 4.35% | 2.60% | |||
| Average Diluted Shares Outstanding | 4.35% | 2.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||